Tesamorelin
FDA ApprovedAlso known as: Egrifta, Egrifta SV, Egrifta WR, TH9507
An FDA-approved GHRH analog for reducing visceral fat in HIV-associated lipodystrophy. One of few GH-releasing peptides with regulatory approval and Phase 3 data.
Research Statistics
Anchor peptide for FDA-approved, US-centric trials. GHRH analog (Egrifta) FDA-approved for HIV-associated lipodystrophy. Substantial US-led clinical trial program; GHRH receptor agonism and GH secretion mechanism is well-characterized. Primarily US research with limited global replication.
Research Dossier
Overview
What is Tesamorelin and what does the research say?
Mechanism of Action
Tesamorelin is a modified version of GHRH (growth hormone-releasing hormone) with FDA approval for HIV-associated lipodystrophy. It works by stimulating your pituitary gland to release growth hormone in natural pulses, targeting visceral fat specifically.
How It Works (Simplified)
Tesamorelin works by mimicking the body’s natural GHRH signal to release growth hormone:
Binds to GHRH receptors on pituitary somatotrophs, triggering natural GH release in physiologic pulses rather than continuous elevation.
GH preferentially mobilizes visceral fat due to higher receptor density and lipolytic sensitivity, sparing subcutaneous fat depots.
Hepatic GH signaling increases IGF-1 production by ~81%, normalizing levels and supporting anabolic and metabolic functions.
Reduces liver fat accumulation and improves hepatic oxidative phosphorylation, with evidence of fibrosis prevention in NAFLD.
Scientific Pathways
GHRH Receptor Signaling (GH Release)
Tesamorelin → GHRH-R binding → Gαs activation → Adenylyl cyclase → ↑cAMP
↓
PKA activation
↓
GH gene transcription + vesicle exocytosis
↓
Pulsatile GH releaseGH Metabolic Effects (Fat Reduction)
GH release → Adipocyte GH receptor binding → HSL activation → Triglyceride hydrolysis
↓
Preferential visceral fat mobilization
↓
↓ VAT (15-27 cm²)Hepatic IGF-1 Axis (Anabolic Signaling)
GH → Hepatic GH receptor → JAK2/STAT5 → IGF-1 gene transcription → ↑IGF-1 (~81%)
↓
Lean mass preservationKey Research: Falutz J et al. (2007) Phase 3 trial demonstrating 15.2% trunk fat reduction vs 5.0% increase with placebo. PMID:18057338
Important Limitations
- Effects do not persist after discontinuation - VAT returns within weeks
- Not approved for general weight loss, anti-aging, or athletic performance
- May impair glucose tolerance - monitor blood glucose
- Contraindicated with active malignancy due to GH/IGF-1 effects
- Short half-life (26-38 min) requires daily administration
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on clinical trials: IGF-1 levels increase by ~81% from baseline. Visceral fat reduction begins. Initial lipolytic effects on trunk fat measurable by imaging.
Continued VAT reduction - Phase 3 trials showed 15.2% trunk fat reduction by week 12. Lean mass may increase (~1.4 kg). Body composition improvements become clinically apparent.
Sustained effects with continued treatment. Mean VAT reduction of 27.7 cm² vs placebo in pooled Phase 3 analysis. Hepatic fat reduction observed in NAFLD studies.
Long-term extension data confirms durability with continued dosing. Effects reverse within weeks of discontinuation - chronic treatment required for maintained benefits.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Tesamorelin product quality
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Tesamorelin with other peptides. Based on published research and mechanistic considerations.
Ipamorelin
SynergisticGHRH+GHRP synergy is well-established. Tesamorelin (GHRH) and ipamorelin (GHRP) act through complementary pathways for enhanced GH release.
GHRP-6
SynergisticClassic GHRH+GHRP combination. Tesamorelin amplifies while GHRP-6 initiates GH pulse. Greater combined effect than either alone.
GHRP-2
SynergisticSynergistic GH release through complementary GHRH and GHRP pathways. No direct combination studies with tesamorelin specifically.
Semaglutide
CautionTesamorelin increases GH which can affect glucose homeostasis. Monitor blood glucose carefully in diabetic patients.
Tirzepatide
CautionGH elevation may impact glucose metabolism. Monitor carefully if combined with incretin-based therapies.
Sermorelin
AvoidBoth are GHRH analogs acting on the same receptor. No benefit to combining; may cause receptor desensitization.
CJC-1295
AvoidBoth are GHRH analogs with identical mechanism. Use one or the other, not both.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Tesamorelin
Tesamorelin Calculators
Related Peptides
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
Related Content
Sermorelin
Hormonal · moderate evidence
CJC-1295
Hormonal · moderate evidence
What is Tesamorelin?
An introduction to tesamorelin (Egrifta), the FDA-approved G...
CJC-1295 vs Tesamorelin
View side-by-side analysis
Sermorelin vs Tesamorelin
View side-by-side analysis